Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

Abstract

BACKGROUND Tandutinib (MLN 518, Millennium Pharmaceuticals, Cambridge, MA) is an orally active multitargeted tyrosine kinase inhibitor that is currently under evaluation for the treatment of glioblastoma and has been used in the treatment of leukemia. In prior clinical and animal studies, a dose-dependent muscular weakness has been observed with this drug… (More)
DOI: 10.1212/WNL.0b013e3182074a69

Topics

Cite this paper

@article{Lehky2011NeuromuscularJT, title={Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.}, author={Tanya J. Lehky and Fabio M. Iwamoto and Teri Nguyen Kreisl and Mary Kay Floeter and Howard A. Fine}, journal={Neurology}, year={2011}, volume={76 3}, pages={236-41} }